Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

JNJ – Johnson & Johnson

Johnson & Johnson
JNJ
$152.45
Name : Johnson & Johnson
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $366,805,352,448.00
EPSttm : 8.99
finviz dynamic chart for JNJ
Johnson & Johnson
$152.45
0.03%
$0.04

Float Short %

0.68

Margin Of Safety %

5

Put/Call OI Ratio

0.76

EPS Next Q Diff

-0.08

EPS Last/This Y

4.77

EPS This/Next Y

0.49

Price

152.44

Target Price

170.84

Analyst Recom

2.2

Performance Q

-6.57

Relative Volume

1.08

Beta

0.4

Ticker: JNJ




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02JNJ155.450.740.98456105
2025-06-03JNJ154.350.760.89473180
2025-06-04JNJ153.490.770.46479084
2025-06-05JNJ153.510.780.81482271
2025-06-06JNJ155.010.780.45482918
2025-06-09JNJ155.20.771.00467103
2025-06-10JNJ156.50.770.93470178
2025-06-11JNJ155.290.780.88479150
2025-06-12JNJ156.660.790.51480398
2025-06-13JNJ157.090.770.39489142
2025-06-16JNJ155.280.770.42474086
2025-06-17JNJ152.520.771.45480395
2025-06-18JNJ150.730.752.03486987
2025-06-20JNJ149.630.750.77488496
2025-06-23JNJ151.290.810.41358647
2025-06-24JNJ152.190.790.46371006
2025-06-25JNJ152.610.770.44383099
2025-06-26JNJ152.050.760.59388163
2025-06-27JNJ152.380.760.76390417
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02JNJ155.44-5.02625.010.61
2025-06-03JNJ154.42-5.02399.410.61
2025-06-04JNJ153.25-5.02362.610.61
2025-06-05JNJ153.66-5.02665.010.61
2025-06-06JNJ155.01-5.02836.210.61
2025-06-09JNJ155.23-5.02619.310.61
2025-06-10JNJ156.50-5.02818.910.61
2025-06-11JNJ155.23-5.02356.310.61
2025-06-12JNJ156.66-5.02842.910.61
2025-06-13JNJ157.05-5.02654.010.61
2025-06-16JNJ155.27-5.02244.610.61
2025-06-17JNJ152.34-5.02044.110.61
2025-06-18JNJ150.73-5.02268.710.61
2025-06-20JNJ149.79-5.02401.710.61
2025-06-23JNJ151.29-5.02870.510.61
2025-06-24JNJ152.21-5.02752.010.61
2025-06-25JNJ152.29-5.02601.810.61
2025-06-26JNJ152.04-5.02533.510.61
2025-06-27JNJ152.44-5.02663.910.61
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02JNJ-0.570.500.95
2025-06-03JNJ-0.570.500.95
2025-06-04JNJ-0.570.500.95
2025-06-05JNJ-0.570.500.95
2025-06-06JNJ-0.570.500.95
2025-06-09JNJ-0.570.530.95
2025-06-10JNJ-0.570.530.95
2025-06-11JNJ-0.570.530.80
2025-06-12JNJ-0.570.530.80
2025-06-13JNJ-0.600.530.80
2025-06-16JNJ-0.600.780.80
2025-06-17JNJ-0.600.780.80
2025-06-18JNJ-0.600.780.80
2025-06-20JNJ-0.600.780.80
2025-06-23JNJ-0.600.820.80
2025-06-24JNJ-0.600.820.80
2025-06-25JNJ-0.600.820.80
2025-06-26JNJ-0.600.820.68
2025-06-27JNJ-0.600.820.68
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

2.77

Avg. EPS Est. Current Quarter

2.68

Avg. EPS Est. Next Quarter

2.69

Insider Transactions

-0.6

Institutional Transactions

0.82

Beta

0.4

Average Sales Estimate Current Quarter

22847

Average Sales Estimate Next Quarter

23099

Fair Value

159.74

Quality Score

97

Growth Score

75

Sentiment Score

76

Actual DrawDown %

18.3

Max Drawdown 5-Year %

-18.4

Target Price

170.84

P/E

16.94

Forward P/E

13.73

PEG

2.87

P/S

4.11

P/B

4.69

P/Free Cash Flow

18

EPS

9

Average EPS Est. Cur. Y​

10.61

EPS Next Y. (Est.)

11.09

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

24.41

Relative Volume

1.08

Return on Equity vs Sector %

4

Return on Equity vs Industry %

-4.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

2663.9
Johnson & Johnson
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 138100
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
stock quote shares JNJ – Johnson & Johnson Stock Price stock today
news today JNJ – Johnson & Johnson stock forecast ,stock prediction 2023 2024 2025
marketwatch JNJ – Johnson & Johnson yahoo finance google finance
stock history JNJ – Johnson & Johnson invest stock market
stock prices JNJ premarket after hours
ticker JNJ fair value insiders trading